Biomedical subjects

M A Monge

Publications and source records attributed to M A Monge.

8 recordsLinked to original sources

PubMed2002

In(2)(OH)(3)(BDC)(1.5) (BDC = 1,4-benzendicarboxylate): an In(III) supramolecular 3D framework with catalytic activity.

The new hybrid inorganic-organic polymer In(2)(OH)(3)[O(4)C(8)H(4)](1.5) has been hydrothermally obtained. Conditions for the synthesis are reported. The crystal structure of this material has been established by single-crystal X-ray diffraction: it is monoclinic, with space group P2(1)/c (Nomicron. 14), a = 6.772(1) A, b = 10.329(2) A, c = 20.152(3) A, beta = 97.573(3) degrees. The In atoms are octahedrally coordinated by three hydroxide groups and three different molecules of carboxylate ligand. The resulting polymeric 3D structure can be envisaged as having been generated from a honeycomb (6,3) 2D that is cross-linked by the BDC organic anions. Data of IR and TGA-DTA studies, as well as the results of reduction of nitroaromatics and selective oxidation of organic sulfide reactions catalyzed by the new material, are reported.

Journal Article↗

PubMed2001

Fermi surface and magnetic structure of TmGa3.

We carry out measurements of the two-dimensional angular correlation of the positron annihilation radiation (2D-ACAR) to reconstruct the complex multisheet Fermi surface (FS) of the cubic rare-earth (RE) compound TmGa3. We discover a correlation between the antiferromagnetic structures and the nesting of the FS along the [110] directions. Moreover, we propose methods to estimate the density of states at the Fermi energy ( EF) and the electronic contribution to the specific heat [we obtain N(EF) = 13.6 states/Ryd cell and gamma = 2.4 mJ/mole K2].

Journal Article↗

PubMed1994

Synthesis, crystal structure, and biological activity of a Pt-dipyridamole salt.

In the present paper we present data on the synthesis, crystal structure and biological activity of bis(dipyridamole) tetrachloroplatinate(II).dipyridamole.dihydrate, [dpmH]2 PtCl4.dpm.2H2O. The crystals are Triclinic P1 with a = 11.490(2) A, b = 13.630(2) A, c = 15.81(1) A, a = 100.97(2) degrees, beta = 100.89(3) degrees, gamma = 112.35(1) degrees, Z = 1, M = 1885.9, Dx = 1.46 g/cm3, MoK alpha (lambda = 0.71069 A), mu = 0.0184 mm-1, R = 4.4%, Rw = 5.0%, 3231 (1 > 2 sigma (I)). The structure is stabilized by a hydrogen-bonding network. It was observed that although dpm alone is not able to alter the electrophoretic mobility of pUC8 DNA forms, the synthesized Pt-dpm compound substantially modifies the DNA conformation since it significantly alters the electrophoretic mobility of nicked and closed circular forms of pUC8 DNA. However, the alteration in mobility of pUC8 DNA induced by this compound upon binding is lower than that induced by cis-DDP. The analysis of the antiproliferative activity of the Pt-dpm salt against MDA-MB 468 (breast carcinoma) and HL-60 (leukemia) human cancer cells showed that this compound has ID50 values of 0.87 microM and 0.65 microM, respectively. Interestingly, it was found out that although the dpm molecule does not present any significant antiproliferative activity, the ID50 values of Pt-dpm are about 3-fold and 7-fold lower than those of cis-DDP and K2PtCl4, respectively. Altogether the biological data suggest that in Pt-dpm a synergic effect between cation and anion is produced.

Antineoplastic Agents↗

PubMed1984